Core Insights - The National Healthcare Security Administration (NHSA) has announced the 2025 version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first edition of the Commercial Health Insurance Innovative Drug Catalog. This marks the eighth consecutive year of adjustments to the drug catalog, which can be interpreted from three perspectives: new drugs, new partners, and new mechanisms [1] Group 1: New Drugs - A total of 114 new drugs have been added to the catalog, enhancing the coverage for critical areas such as cancer and chronic diseases. Among these, 111 are new products launched within the last five years, accounting for 97.3% of the additions [2] - The new drugs address clinical treatment gaps, including innovative therapies for major diseases like breast cancer, pancreatic cancer, and lung cancer, as well as medications for rare diseases and chronic conditions such as diabetes and high cholesterol [2][3] Group 2: New Partners - The recent innovative drug high-quality development conference included a diverse range of participants, such as investors, fund managers, and representatives from commercial insurance institutions, alongside traditional stakeholders like the NHSA and pharmaceutical companies. This indicates a growing recognition of the importance of innovation in healthcare [4] - The involvement of new partners reflects the understanding that healthcare is both a public welfare issue and an industry, highlighting the ongoing interest and investment from the capital market in pharmaceutical innovation [4] Group 3: New Mechanisms - The commercial insurance innovative drug catalog was released simultaneously with the basic medical insurance drug catalog. This addresses the ongoing debate regarding the inclusion of high-cost drugs in basic insurance coverage [5] - A total of 121 drugs met the criteria for the commercial insurance innovative drug catalog, with 19 ultimately included. This catalog features advanced treatment methods such as CAR-T and T-cell therapies, as well as medications for rare diseases and Alzheimer's, complementing the basic insurance offerings [5]

2025年国家医保药品目录及首版商保创新药目录在广州发布。2025年国家医保药品目录成功新增114种 药品，有50种是一类创新药，总体成功率88%，较2024年的76%明显提高。19种药品纳入首版商保创新 药目录。 2025年国家医保药品目录纳入了一些弥补基本医保保障空白的药品，如三阴乳腺癌、胰腺癌、肺癌等重 大疾病用药；朗格汉斯细胞组织细胞增生症、螯合剂不耐受的地中海贫血症等罕见病用药；糖尿病、高 胆固醇血症、自身免疫性疾病等慢性病用药。 （原标题：2025医保药品目录公布 新增药品114种） 此次调整后，国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性 病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。 （来源：央视新闻） 纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕 见病治疗药品，还有阿尔茨海默病治疗药品等。 ...

新华社记者12月7日从国家医保局获悉，2025年国家医保药品目录及首版商保创新药目录在广州发布。 2025年国家医保药品目录成 功新增114种药品，有50种是一类创新药 ，总体成功率88%，较2024年的76%明显提高。 19种药品纳入首版商保创新药目录。 此次调整后， 国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种 ，肿瘤、慢性病、精神疾病、罕见病、 儿童用药等重点领域的保障水平得到明显提升。 来源丨新华社 编辑丨刘雪莹 百万一针抗癌神药有望降至10万以下 Space X冲击5.7万亿估值，马斯克深夜回应 芯片重要并购终止，双方均有小米系参股 SFC 2 1君荐读 2025年国家医保药品目录纳入了一些弥补基本医保保障空白的药品， 如三阴乳腺癌、胰腺癌、肺癌等重大疾病用药；朗格汉斯细胞 组织细胞增生症、螯合剂不耐受的地中海贫血症等罕见病用药；糖尿病、高胆固醇血症、自身免疫性疾病等慢性病用药。 纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕见病治疗药品，还有阿尔茨 海默病治疗药品等。 ...

新华社权威快报 2025年药品目录谈判协商结果12月7日在广州发布 114神药品 进入国家医保药品目录 此次调整后，国家医保药品目录内药品总数增至3253种，其中西药1857种、中成药1396种，肿瘤、慢性 病、精神疾病、罕见病、儿童用药等重点领域的保障水平得到明显提升。 原标题：114种新药进入2025年国家医保药品目录 编辑：牟慧兰 责编：杨四海 新华社消息，记者12月7日从国家医保局获悉，2025年国家医保药品目录及首版商保创新药目录在广州发 布。2025年国家医保药品目录成功新增114种药品，有50种是一类创新药，总体成功率88%，较2024年的 76%明显提高。19种药品纳入首版商保创新药目录。 2025年国家医保药品目录纳入了一些弥补基本医保保障空白的药品，如三阴乳腺癌、胰腺癌、肺癌等重大 疾病用药；朗格汉斯细胞组织细胞增生症、螯合剂不耐受的地中海贫血症等罕见病用药；糖尿病、高胆固 醇血症、自身免疫性疾病等慢性病用药。 纳入首版商保创新药目录的19种药品中，既有CAR-T等肿瘤治疗药品，也有神经母细胞瘤、戈谢病等罕见 病治疗药品，还有阿尔茨海默病治疗药品等。 19神药品 纳入首版商保创新药目录 2 ...

Core Insights - The National Healthcare Security Administration (NHSA) has initiated negotiations for the 2025 National Basic Medical Insurance (BMI) drug list and the commercial insurance innovative drug list from October 30 to November 3, with participation from 120 domestic and foreign enterprises [1] - This year marks a significant change as the commercial insurance innovative drug list has been added to the directory adjustment process, running concurrently with the basic medical insurance directory work [1] - The new basic medical insurance drug list and the first version of the commercial insurance innovative drug list are expected to be released online and offline in Guangzhou on the first weekend of December, with implementation set for January 1, 2026 [1] Summary by Categories Negotiation and Participation - A total of 127 drugs outside the directory participated in the BMI drug list negotiations, while 24 drugs were involved in the price negotiations for the commercial insurance innovative drug list [1] Changes in Drug Listing Process - The inclusion of the commercial insurance innovative drug list in the directory adjustment process represents a new approach compared to previous years, indicating a shift towards integrating commercial insurance with basic medical insurance [1] Timeline for Implementation - The NHSA plans to complete the necessary technical, administrative, and legal procedures before the release of the new drug lists, which will be officially implemented starting January 1, 2026 [1]

Core Points - The new basic medical insurance drug catalog and the first version of the commercial insurance innovative drug catalog are set to be released in Guangzhou on the first weekend of December, with implementation starting on January 1, 2024 [1] - The recent negotiations involved 120 domestic and foreign enterprises, with 127 drugs outside the basic medical insurance catalog participating in the negotiations, and 24 drugs involved in price negotiations for the commercial insurance innovative drug catalog [3] - The commercial insurance innovative drug catalog was organized by the National Medical Insurance Administration, allowing companies to apply for inclusion in either the basic medical insurance catalog or the commercial insurance innovative drug catalog, or both [5] Industry Insights - The addition of the commercial insurance innovative drug catalog aims to better meet the diverse medication needs of the population, with 1.326 billion people covered by basic medical insurance in 2024, maintaining a coverage rate of 95% [6] - Total expenditure for the basic medical insurance fund is projected to reach 2.97 trillion yuan in 2024, providing solid support for healthcare access [6] - The commercial health insurance market is experiencing rapid growth, with premium income reaching 977.3 billion yuan in 2024, an increase of 8.2% year-on-year, although there remains significant room for improvement in coverage levels compared to basic medical insurance [6] - Challenges exist in synchronizing medical insurance and commercial insurance settlements across provinces, but initiatives like the "commercial insurance + medical insurance" one-stop settlement payment platforms have been launched in various regions [6]

Core Viewpoint - The recent claim that only 3,159 out of over 150,000 approved drugs are included in the national medical insurance directory, representing only 2%, is misleading and based on different statistical standards [1][2]. Group 1: Drug Approval and Insurance Coverage - The National Medical Insurance Bureau clarified that the comparison of the number of approved drugs and those in the insurance directory is flawed due to differing statistical criteria [1][3]. - The number of drugs in the insurance directory (3,159) is based on active ingredients, while the total approved drugs (over 150,000) includes multiple brand names and approval numbers for the same drug [2][3]. - When standardized, the number of approval numbers for the drugs in the insurance directory exceeds 70,000, accounting for approximately 63% of the drugs with sales records in the market [3][6]. Group 2: Drug Directory Adjustments and Clinical Relevance - The National Medical Insurance Bureau has adjusted the drug directory for seven consecutive years, adding 835 drugs and removing 438 that are ineffective or outdated [4][5]. - The current directory includes essential drugs for major diseases, with a focus on maintaining a balance between clinical necessity and economic feasibility [5][6]. - The quality and structure of the drugs in the insurance directory have improved significantly, with a more reasonable cost level and enhanced coverage [6]. Group 3: Policy Implications and Future Considerations - The insurance policy aims to provide basic drug coverage while considering the financial capacity of the insurance fund and the overall social burden [6]. - The focus is on optimizing the structure of the drug directory rather than merely increasing the percentage of covered drugs, emphasizing the importance of addressing significant health needs, especially for chronic diseases [6].

Core Insights - The National Healthcare Security Administration (NHSA) of China has publicly announced the preliminary review results for the 2025 National Medical Insurance Drug List, indicating a significant increase in the number of drug names passing the initial review compared to 2024 [1] Group 1: Drug List Review - A total of 718 submissions for the basic medical insurance drug list were received, involving 633 drug names, with 534 passing the preliminary review [1] - For the 2024 review, only 249 drug names passed, showing a notable increase in successful submissions this year [1] Group 2: Commercial Insurance Drug List - The NHSA has introduced a new commercial insurance innovative drug list, which was submitted concurrently with the basic medical insurance list [1] - There were 141 submissions for the commercial insurance innovative drug list, with 121 drug names passing the preliminary review [1] Group 3: Review Process Clarification - The NHSA emphasized that passing the preliminary review only indicates compliance with submission conditions and does not guarantee inclusion in the final drug lists [1] - The drugs that pass the preliminary review will still undergo public scrutiny before being officially included in the basic medical insurance or commercial insurance innovative drug lists [1]

Group 1 - The National Medical Insurance Administration (NMIA) announced the preliminary results of the 2025 National Medical Insurance Drug List review, with 534 drugs passing the formal review, indicating an increase in the number of drug applications compared to 2024 [1] - The adjustment process for the medical insurance drug list includes several stages: enterprise application, formal review, expert evaluation, negotiation and bidding, and price consultation [1] - A new category for commercial insurance innovative drugs has been added this year, with 141 generic drug names submitted for review, of which 121 passed the formal review [1] Group 2 - Some drugs applied for both the basic medical insurance list and the commercial insurance innovative drug list, leading to potential discrepancies in the review results due to differing application criteria [1] - Expensive drugs that exceed the basic medical insurance coverage may pass the preliminary formal review, but their final inclusion in the basic medical insurance list depends on strict evaluation procedures, including successful negotiations for exclusive drugs and competitive bidding for non-exclusive drugs [1] - The public consultation period for the announced results will end on August 18, during which the NMIA will review feedback and finalize the list of drugs that passed the formal review [2]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has published the preliminary results of the initial review for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog adjustments, as well as the commercial health insurance innovative drug catalog adjustments, indicating a structured approach to drug approval and transparency in the process [1][2]. Group 1: Initial Review Process - The initial review serves to verify whether the submitted drugs meet the application conditions for the basic medical insurance and commercial health insurance innovative drug catalogs, ensuring the completeness and compliance of the application materials [1][2]. - The review process consists of four steps: initial review, public announcement of results, re-examination, and announcement of re-examination results, with the current publication representing the initial review results [1][3]. Group 2: Comparison with Previous Year - From July 11 to July 20, 2025, the NHSA received 718 applications for the basic medical insurance catalog, involving 633 drug generic names, with 534 passing the initial review, a significant increase from 249 in 2024 [4]. - The newly established commercial health insurance innovative drug catalog received 141 applications, with 121 drug generic names passing the initial review, indicating a robust interest in both catalogs [4]. Group 3: High-Cost Drugs and Review Implications - The NHSA emphasizes that passing the initial review does not guarantee inclusion in the basic medical insurance catalog, as further evaluations and negotiations are required, especially for high-cost drugs that exceed basic coverage [4][5]. - The agency aims to balance basic medical needs with clinical advancements while maintaining the sustainability of the insurance fund, indicating a cautious approach to including expensive drugs in the catalog [4]. Group 4: Next Steps - Following the public announcement, the NHSA will review feedback received during the public comment period to finalize the list of drugs that passed the initial review and will communicate the results to the applicants [6]. - The NHSA will proceed with expert evaluations, negotiations for the basic medical insurance catalog, and price discussions for the commercial health insurance innovative drug catalog as part of the ongoing adjustment process [6].